These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 38429828)

  • 21. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.
    Kim EG; Kim KM
    Biomol Ther (Seoul); 2015 Nov; 23(6):493-509. PubMed ID: 26535074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjugates of Small Molecule Drugs with Antibodies and Other Proteins.
    Feng Y; Zhu Z; Chen W; Prabakaran P; Lin K; Dimitrov DS
    Biomedicines; 2014 Jan; 2(1):1-13. PubMed ID: 28548057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired Resistance to Antibody-Drug Conjugates.
    Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.
    Babbar R; Vanya ; Bassi A; Arora R; Aggarwal A; Wal P; Dwivedi SK; Alolayan S; Gulati M; Vargas-De-La-Cruz C; Behl T; Ojha S
    Heliyon; 2023 Nov; 9(11):e21425. PubMed ID: 38027672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.
    Dan N; Setua S; Kashyap VK; Khan S; Jaggi M; Yallapu MM; Chauhan SC
    Pharmaceuticals (Basel); 2018 Apr; 11(2):. PubMed ID: 29642542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment.
    Xu X; Zhang J; Wang T; Li J; Rong Y; Wang Y; Bai C; Yan Q; Ran X; Wang Y; Zhang T; Sun J; Jiang Q
    Acta Pharm Sin B; 2024 Apr; 14(4):1542-1559. PubMed ID: 38572098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
    Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
    Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs.
    Metrangolo V; Engelholm LH
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer.
    Yu Y; Wang J; Liao D; Zhang D; Li X; Jia Y; Kong F
    Breast Cancer (Dove Med Press); 2022; 14():417-432. PubMed ID: 36532256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.
    Aggarwal D; Yang J; Salam MA; Sengupta S; Al-Amin MY; Mustafa S; Khan MA; Huang X; Pawar JS
    Front Immunol; 2023; 14():1203073. PubMed ID: 37671162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer.
    Xu J; Li X; Du Y
    Adv Biol (Weinh); 2022 Mar; 6(3):e2101065. PubMed ID: 35122418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Chemistry Behind ADCs.
    Kostova V; Désos P; Starck JB; Kotschy A
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34067144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.
    Gauzy-Lazo L; Sassoon I; Brun MP
    SLAS Discov; 2020 Sep; 25(8):843-868. PubMed ID: 32192384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives.
    Li K; Xie G; Deng X; Zhang Y; Jia Z; Huang Z
    Front Oncol; 2023; 13():1259784. PubMed ID: 38173833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.